Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma
Durvalumab and bevacizumab in addition to transarterial chemoembolisation (TACE) is in clinical development for treating patients with locoregional hepatocellular carcinoma (HCC). HCC is the most common type of primary liver cancer in adults and the most common cause of death in people with cirrhosis (scarring of the liver). It usually presents at an advanced stage and has a poor prognosis. The current standard of care can only slow the progression of the cancer and extend survival.
Durvalumab and bevacizumab are drugs given through intravenous infusion that act through different pathways to stimulate the body’s immune system to fight cancerous cells. TACE involves giving chemotherapy directly to the tumour through an injection. The combined effect of the two products and TACE may produce a stronger more targeted immune response against the cancer cells when compared to current treatments. If licensed durvalumab in combination with bevacizumab and TACE could provide an additional efficacious and safe treatment option for patients with locoregional HCC.